HEPA Archives - BioTuesdays

Developments

Hepion discovers novel rencofilstat action in liver cancer

Hepion Pharmaceuticals (NASDAQ:HEPA) reported new research findings that discovered a mechanism by which the company’s lead drug candidate, rencofilstat, may exert anti-cancer activity. The research examined...

September 20, 2023

Developments

Hepion’s rencofilstat shows positive outcomes in idiopathic pulmonary fibrosis

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive findings from a translational research study assessing the effects of rencofilstat on lung tissue obtained from patients with idiopathic pulmonary fibrosis (IPF)...

September 14, 2023

Developments

Hepion to present 2 posters at EASL International Liver Congress

Hepion Pharmaceuticals (NASDAQ:HEPA) will present two abstracts for poster presentations at the European Association for the Study of the Liver (EASL) International Liver Congress 2023 taking place June 21 – 24 in...

June 16, 2023

Developments

Hepion Phase 2b ASCEND-NASH trial passes key safety milestone

A data and safety monitoring board (DSMB) has reviewed the current data for Hepion Pharmaceuticals’ (NASDAQ:HEPA) ASCEND-NASH Phase 2b trial with rencofilstat and issued a “study may proceed without modification”...

June 15, 2023

Developments

Hepion to highlight AI-POWR at medical conference

Hepion Pharmaceuticals (NASDAQ:HEPA) will outline the integration of its artificial intelligence and machine learning platform, AI-POWR, into all aspects of its clinical pharmacological programs at the 2023 Canadian...

May 25, 2023

Markets

Analysts give high marks to Hepion’s ATTITUDE NASH trial results

Analysts for Cantor Fitzgerald and Brookline Capital Markets gave high marks to Hepion Pharmaceuticals’ (NASDAQ:HEPA) Phase 2a ATTITUDE NASH trial results, which met its primary and secondary endpoints as well as showed...

May 22, 2023

Developments

Hepion Phase 2 ALTITUDE-NASH trial achieves all endpoints, improvement in liver function and NASH biomarkers

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive topline results from its recently completed Phase 2 ALTITUDE-NASH clinical trial with lead drug candidate, rencofilstat. ALTITUDE-NASH met its primary endpoint by...

May 22, 2023

Developments

Hepion to release Phase 2 ALTITUDE-NASH results pre-market on May 22

Hepion Pharmaceuticals (NASDAQ:HEPA) expects to release topline results from the Phase 2 ALTITUDE-NASH clinical trial with its rencofilstat drug candidate before the market opens on Monday, May 22, 2023. The company...

May 19, 2023

Markets

Cantor and Brookline change Hepion PTs to $28 and $74 post-split

Cantor Fitzgerald raised its price target for Hepion Pharmaceuticals (NASDAQ:HEPA) to $28 after a one-for-20 reverse stock split on May 10, and maintained an “overweight” rating. The stock closed at $6.81 on Friday. “We...

May 15, 2023

Developments

Hepion to present data on synergistic effects of rencofilstat with anti-PD1 at AACR

Daren Ure, Ph.D., CSO of Hepion Pharmaceuticals (NASDAQ:HEPA) will present an abstract on April 18 highlighting the company’s lead drug candidate, rencofilstat, at the American Association for Cancer Research annual...

April 18, 2023

Tag - HEPA

Hepion discovers novel rencofilstat action in liver cancer

Hepion’s rencofilstat shows positive outcomes in idiopathic pulmonary fibrosis

Hepion to present 2 posters at EASL International Liver Congress

Hepion Phase 2b ASCEND-NASH trial passes key safety milestone

Hepion to highlight AI-POWR at medical conference

Analysts give high marks to Hepion’s ATTITUDE NASH trial results

Hepion Phase 2 ALTITUDE-NASH trial achieves all endpoints, improvement in liver function and NASH biomarkers

Hepion to release Phase 2 ALTITUDE-NASH results pre-market on May 22

Cantor and Brookline change Hepion PTs to $28 and $74 post-split

Hepion to present data on synergistic effects of rencofilstat with anti-PD1 at AACR

General

More